You are leaving the 51³Ô¹ÏÍø¹ÙÍøs website. By clicking this link, you will be taken to a website that is independent from 51³Ô¹ÏÍø¹ÙÍøs. The site you are linking to is not controlled or endorsed by 51³Ô¹ÏÍø¹ÙÍøs and 51³Ô¹ÏÍø¹ÙÍøs is not responsible for the content provided on that site.
51³Ô¹ÏÍø¹ÙÍøs is a clinical stage radiopharmaceutical company dedicated to the advancement of next generation targeted radiotherapeutics to treat cancer patients. With proven leadership and therapeutic radiopharmaceutical expertise, 51³Ô¹ÏÍø¹ÙÍøs has a strong pipeline of precision targeted radiopharmaceuticals. The initial focus is on prostate cancer with plans to expand to additional cancer types.
The approach of 51³Ô¹ÏÍø¹ÙÍøs is to build on the progress seen with first generation radiopharmaceuticals with unique, targeted radio hybrid agents.
